Results 61 to 70 of about 19,540 (227)
Pathogen‐reduced plasma, cryoprecipitate reduced for therapeutic plasma exchange
Transfusion, EarlyView.Abstract Background Therapeutic plasma exchange (TPE) for thrombotic thrombocytopenic purpura (TTP) and auto‐immune disorders involves repeated patient exposure to allogenic plasma with the risk of transfusion‐transmitted infection (TTI).
Florian Tupin +6 more
wiley +1 more source
Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency. [PDF]
, 1988 Human-human B cell hybridomas constructed from B lymphocytes of common variable immunodeficiency (CVI) patients and the nonsecreting cell line WIL2/729 HF consistently secrete low levels of Ig and appear to retain a defect characteristic of the CVI ...
Adelman, DC +5 more
core
Pediatric Blood &Cancer, Volume 73, Issue 2, February 2026.ABSTRACT Children undergoing allogeneic stem cell transplantation often receive off‐label rituximab treatment for Epstein–Barr virus reactivation, using adult dosing without pediatric evidence. This project aims to develop a clinical decision support tool (CDSS) that provides evidence‐based dosing scenarios by analyzing real‐world patient data.
Birgit Burkhardt +2 more
wiley +1 more source
Namık Kemal Tıp Dergisi, 2021 Aim:Atopic dermatitis (AD) is the most common chronic skin disease of childhood. Although eczema may be a prominent finding in some primary immune deficiencies, there are very few studies conducted on the frequency of hypogammaglobulinemia in patients ...
Burçin BEKEN +3 more
doaj +1 more source
Cost of Serious Infections in Chronic Lymphocytic Leukemia
Cancer Medicine, Volume 15, Issue 2, February 2026.ABSTRACT Background The economic burden of chronic lymphocytic leukemia (CLL) is high, and is projected to increase with the introduction of new targeted treatments and improved survival. These high costs are not only associated with anticancer treatment, but also with the treatment and prevention of CLL symptoms and adverse events.
Sara Carrillo de Albornoz +5 more
wiley +1 more source
Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. [PDF]
, 2009 We observed that high-dose methylprednisolone (HDMP) and rituximab was well tolerated and had promising activity when used in combination to treat patients with fludarabine-refractory chronic lymphocytic leukemia (CLL).
Bole, J +6 more
core
Subcutaneous IgG Replacement Therapy by Push in 32 Patients with Primary Immunodeficiency Diseases in Argentine [PDF]
, 2014 Introduction: Regular replacement with immunoglobulin infusions is the mainstay of treatment in the majority of primary immunodeficiencies. Several studies showed that Subcutaneous Immunoglobulin (SCIG) has similar efficacy to Intravenous Immunoglobulin (
Bezrodnik, Liliana +6 more
core +1 more source
Cancer Medicine, Volume 15, Issue 2, February 2026.ABSTRACT Introduction Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphoma, and despite advances in frontline therapies such as rituximab, cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), vincristine sulfate (Oncovin), and prednisone, approximately 30%–40% of patients develop relapsed or refractory (
Dana Sofian Abou +6 more
wiley +1 more source
Pragmatic treatment of patients with Systemic Lupus Erythematosus with rituximab: Long-term effects on serum immunoglobulins [PDF]
, 2016 OBJECTIVE: B cell depletion therapy based on rituximab is a therapeutic option for refractory disease in patients with Systemic Lupus Erythematosus (SLE).
Cambridge, G +4 more
core
The lung in primary immunodeficiencies: new concepts in infection and inflammation [PDF]
, 2018 Immunoglobulin replacement therapy (IGRT) has contributed critically to the management of primary antibody deficiencies (PAD) and the decrease in pneumonia rate.
Baumann, Ulrich +4 more
core +4 more sources